Centralising analytical data from mass spectrometry in drug discovery and development

Make your data FAIR, AI-ready, and built to scale
 

Mass spectrometry is critical in drug discovery — but legacy systems, data silos, and poor metadata are slowing progress.
This white paper, in partnership with Thermo Fisher, shares how experts from Zoetis, Bayer, LifeMine Therapeutics, Iterion, Targenomix, and the Pistoia Alliance are solving key data challenges.
 

Inside:
 

• Strategies to centralise and standardise MS data
• How to make data FAIR and ready for AI/ML
• Tips for better collaboration across teams and with CROs

“AI is only as good as the data it learns from. Without structure, you can’t trust the output.”
— Birthe Nielsen, Pistoia Alliance